Guardado Miguel, Torgerson Dara, Chapin Cheryl, Atum Azuka, Hernandez Ryan D, Clyman Ronald, Simmons Rebecca, Parry Samuel, Ballard Philip L
Department of Biological and Medical Informatics, University of California, San Francisco, San Francisco, California.
Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.
Am J Perinatol. 2025 Sep;42(12):1576-1587. doi: 10.1055/a-2512-9387. Epub 2025 Jan 9.
Extremely premature infants are treated with acetaminophen (APAP) for pain and patent ductus arteriosus. High doses of APAP in adults are toxic, and a recent study found an association between APAP metabolite levels in mothers' breast milk and both bronchopulmonary dysplasia (BPD) and retinopathy of prematurity (ROP) in their premature infants. In this study, we determined levels of APAP metabolites in the urine of infants at high risk for BPD and ROP.Biorepository urine samples from 314 infants <29 weeks' gestation in the multicenter TOLSURF and PROP studies were analyzed by untargeted UHPLC:MS/MS (Metabolon, Inc.). We performed multivariate logistic regression and meta-analysis to examine associations between APAP metabolite levels and clinical outcomes.4-APAP sulfate was the most abundant of eight detected APAP metabolites and was present in 95% of urines. There were high correlations between levels of 4-APAP sulfate and the other APAP metabolites. In longitudinal studies on a subgroup of infants (day 6-56), periods of elevated 4-APAP sulfate occurred in 24/28 infants and were of longer duration (10.5 vs. 4.2 days, = 0.001) with higher levels (13.3 vs. 5.6, = 0.01) in infants after transition to enteral from total parenteral nutrition. Episodes of elevated metabolite did not differ by BPD status. On both days 10 and 28 there were no significant associations between levels of APAP metabolites and either BPD or ROP for all infants or for infants exclusively on parenteral or enteral nutrition.In two cohorts of extremely premature infants, levels of urinary APAP metabolites were not associated with increased risk for two adverse clinical outcomes. · Safety of acetaminophen (APAP) in extremely premature infants has not been established.. · The major urinary APAP metabolite was detected in the majority of urine samples.. · No association was found between APAP levels and either bronchopulmonary dysplasia or retinopathy of prematurity..
极早早产儿会使用对乙酰氨基酚(APAP)来缓解疼痛和治疗动脉导管未闭。成人使用高剂量的APAP是有毒的,并且最近一项研究发现,母亲母乳中APAP代谢物水平与她们早产婴儿的支气管肺发育不良(BPD)和早产儿视网膜病变(ROP)之间存在关联。在本研究中,我们测定了有BPD和ROP高风险婴儿尿液中APAP代谢物的水平。在多中心TOLSURF和PROP研究中,对314名妊娠<29周的婴儿的生物样本库尿液样本采用非靶向超高效液相色谱-串联质谱法(Metabolon公司)进行分析。我们进行了多变量逻辑回归和荟萃分析,以检验APAP代谢物水平与临床结局之间的关联。4-APAP硫酸盐是检测到的8种APAP代谢物中含量最丰富的,存在于95%的尿液中。4-APAP硫酸盐水平与其他APAP代谢物水平之间存在高度相关性。在对一组婴儿(第6 - 56天)的纵向研究中,24/28名婴儿出现了4-APAP硫酸盐水平升高的时期,从全胃肠外营养过渡到肠内营养后,婴儿的升高持续时间更长(10.5天对4.2天,P = 0.001),水平更高(13.3对5.6,P = 0.01)。代谢物水平升高的发作在BPD状态方面没有差异。在第10天和第28天,对于所有婴儿或仅接受胃肠外或肠内营养的婴儿,APAP代谢物水平与BPD或ROP之间均无显著关联。在两组极早早产儿中,尿液中APAP代谢物水平与两种不良临床结局风险增加无关。· 对乙酰氨基酚(APAP)在极早早产儿中的安全性尚未确立。· 在大多数尿液样本中检测到了主要的尿液APAP代谢物。· 未发现APAP水平与支气管肺发育不良或早产儿视网膜病变之间存在关联。